Last reviewed · How we verify
Attruby (ACORAMIDIS)
Attruby works by stabilizing the transthyretin protein to prevent its misfolding and aggregation into amyloid fibrils.
At a glance
| Generic name | ACORAMIDIS |
|---|---|
| Sponsor | Bridgebio Pharma |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 2024 |
Mechanism of action
Acoramidis is a selective stabilizer of transthyretin (TTR). Acoramidis binds TTR at thyroxine binding sites and slows dissociation of the TTR tetramer into its constituent monomers, the rate-limiting step in amyloidogenesis.
Approved indications
- Cardiomyopathy of ATTR-CM
Common side effects
- Diarrhea
- Upper abdominal pain
- Increase in Serum Creatinine
- Decrease in eGFR
- Discontinuation due to adverse event
Drug interactions
- UGT inducers
- Strong CYP3A inducers
- UGT inducers
- Strong CYP3A inducers
- Sensitive CYP2C9 substrates
Key clinical trials
- Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant (PHASE3)
- Study to Assess the Effect of Food on a Single Dose of Acoramidis in Healthy Adult Participants (PHASE1)
- A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis (PHASE4)
- A Phase 3 Study of ALXN2060 in Japanese Participants With Symptomatic ATTR-CM (PHASE3)
- Real-Life Clinical Efficacy of Acoramidis in Participants With ATTR-CM and Association With Cardiac Biomarkers (PHASE4)
- Determining the Association of TTR Stabilizing Therapy With Circulating TTR Amyloid Aggregates Over Time in Patients With ATTR-CM: Longitudinal Biomarker Study
- A Study to Learn About the Use of Acoramidis in Patients With a Heart Condition Called Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in a Real-world Setting
- Open-Label Safety Study of Acoramidis (AG10) in Symptomatic ATTR Participants (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Attruby CI brief — competitive landscape report
- Attruby updates RSS · CI watch RSS
- Bridgebio Pharma portfolio CI